Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals. For the full story, visit the source.
Business
Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.
By Srushti Vaidya· Livemint· 8 days ago· 2 min read
This summary is sourced from Livemint. Read the full article at:Livemint